Use of substituted cyclopropane acid derivative in treating metabolic syndrome medicineCompositions are given that have high viscosities at one pH range and low viscosities at another pH range. Methods are given for using such compositions in oilfield treatments. In particular CT wellbore cleanout compositions and methods are given in which a viscous fluid is injected into a wellbore; the fluid entrains particles and carries them to the surface; the viscosity of the fluid is reduced by reducing or increasing the pH; the particles settle from the fluid; the viscosity of the fluid is increased by increasing or reducing the pH; and the fluid is re-injected into the wellbore. Suitable surfactants are anionic surfactants, or mixtures of surfactants containing anionic surfactants, that aggregate into three-dimensional structures that substantially increase the viscosity at high pH but not at low pH. Other suitable surfactants are cationic surfactants with co-surfactants that aggregate below a certain pH but not above.The salt that can tolerate on formula i chemical compound and the physiology thereof is used for the treatment of purposes in the medicine of metabolism syndrome in preparation,wherein implication isr1 is h, (c 1-c 20)-alkyl, (c 2-c 20)-alkenyl, (c 2-c 20)-alkynyl, aryl, heterocyclic radical, wherein alkyl, alkenyl, alkynyl, aryl and heterocyclic radical can be replaced one or many by following groups: f, cl, br, i, cf 3, no 2, n 3, cn, cooh, coo (c 1-c 6)-alkyl, conh 2, conh (c 1-c 6)-alkyl, con[(c 1-c 6)-alkyl] 2, cyclic hydrocarbon radical, (c 1-c 10)-alkyl, (c 2-c 6)-alkenyl, (c 2-c 6)-alkynyl, o-(c 1-c 6)-alkyl o-co-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-aryl, o-co-(c 1-c 6)-heterocyclic radical; po 3h 2, p (o) (o alkyl) 2, (c 1-c 6)-alkylidene-p (o) (o alkyl) 2, o-p (o) (oh) 2, o-p (o) (o alkyl) 2, so 3h, so 2-nh 2, so 2nh (c 1-c 6)-alkyl, so 2n[(c 1-c 6)-alkyl] 2, s-(c 1-c 6)-alkyl, s-(ch 2) n-aryl, s-(ch 2) n-heterocyclic radical, so-(c 1-c 6)-alkyl, so-(ch 2) n-aryl, so-(ch 2) n-heterocyclic radical, so 2-(c 1-c 6)-alkyl, so 2-(ch 2) n-aryl, so 2-(ch 2) n-heterocyclic radical, so 2-nh (ch 2) n-aryl, so 2-nh (ch 2) n-heterocyclic radical, so 2-n ((c 1-c 6)-alkyl) (ch 2) n-aryl, so 2-n ((c 1-c 6)-alkyl) (ch 2) n-heterocyclic radical, so 2-n ((ch 2) n-aryl) 2, so 2-n ((ch 2) n-(heterocyclic radical) 2, wherein n can be 0-6, and aryl or heterocyclic radical can be replaced twice at the most by following groups: f, cl, br, oh, cf 3, sf 5, no 2, cn, ocf 3, o-(c 1-c 6)-alkyl, (c 1-c 6)-alkyl, nh 2c (nh) (nh 2), nh 2, nh-(c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, nh (c 1-c 7)-acyl group, nh-co-(c 1-c 6)-alkyl, nh-coo-(c 1-c 6)-alkyl, nh-co-aryl, nh-co-heterocyclic radical, nh-coo-aryl, nh-coo-heterocyclic radical, nh-co-nh-(c 1-c 6)-alkyl), nh-co-nh-aryl, nh-co-nh-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-(c 1-c 6)-alkyl, n[(c 1-c 6)-alkyl]-coo-(c 1-c 6)-alkyl, n[(c 1-c 6)-alkyl]-co-aryl, n[(c 1-c 6)-alkyl]-co-heterocyclic radical, n[(c 1-c 6)-alkyl]-coo-aryl, n[(c 1-c 6)-alkyl]-coo-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-nh-(c 1-c 6)-alkyl), n[(c 1-c 6)-alkyl]-co-nh-aryl, n[(c 1-c 6)-alkyl]-co-nh-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-n ((c 1-c 6)-alkyl) 2, n[(c 1-c 6)-alkyl]-co-n ((c 1-c 6)-alkyl)-aryl, n[(c 1-c 6)-alkyl]-co-n ((c 1-c 6)-alkyl)-heterocyclic radical, n[(c 1-c 6)-alkyl]-co-n (aryl) 2, n[(c 1-c 6)-alkyl]-co-n (heterocyclic radical) 2, n (aryl)-co-(c 1-c 6)-alkyl, n (heterocyclic radical)-co-(c 1-c 6)-alkyl, n (aryl)-coo-(c 1-c 6)-alkyl, n (heterocyclic radical)-coo-(c 1-c 6)-alkyl, n (aryl)-co-aryl, n (heterocyclic radical)-co-aryl, n (aryl)-coo-aryl, n (heterocyclic radical)-coo-aryl, n (aryl)-co-nh-(c 1-c 6)-alkyl, n (heterocyclic radical)-co-nh-(c 1-c 6)-alkyl, n (aryl)-co-nh-aryl, n (heterocyclic radical)-co-nh-aryl, n (aryl)-co-n ((c 1-c 6)-alkyl) 2, n (heterocyclic radical)-co-n ((c 1-c 6)-alkyl) 2, n (aryl)-co-n[(c 1-c 6)-alkyl]-aryl, n (heterocyclic radical)-co-n[(c 1-c 6)-alkyl]-aryl, n (aryl)-co-n (aryl) 2, n (heterocyclic radical)-co-n (aryl) 2, aryl, o-(ch 2) n-aryl, o-(ch 2) n-heterocyclic radical, wherein n can be 0-6, wherein aryl or heterocyclic radical can be replaced 1-3 time by following groups: f, cl, br, i, oh, cf 3, no 2, cn, ocf 3, o-(c 1-c 6)-alkyl, (c 1-c 6)-alkyl, nh 2, nh (c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, sf 5, so 2-ch 3, cooh, coo-(c 1-c 6)-alkyl, conh 2r2 is (c 1-c 20)-alkyl, (c 2-c 20)-alkenyl, (c 2-c 20)-alkynyl, aryl, (c 3-c 7)-cyclic hydrocarbon radical, heterocyclic radical, wherein alkyl, alkenyl, alkynyl, aryl, cyclic hydrocarbon radical and heterocyclic radical can be replaced one or many by following groups: f, cl, br, i, cf 3, no 2, n 3, cn, cooh, coo (c 1-c 6) alkyl, conh 2, conh (c 1-c 6) alkyl, con[(c 1-c 6) alkyl] 2, cyclic hydrocarbon radical, (c 1-c 10)-alkyl, (c 2-c 6)-alkenyl, (c 2-c 6)-alkynyl, o-(c 1-c 6)-alkyl o-co-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-aryl, o-co-(c 1-c 6)-heterocyclic radical; po 3h 2, p (o) (o alkyl) 2, (c 1-c 6)-alkylidene-p (o) (o alkyl) 2, o-p (o) (oh) 2, o-p (o) (o alkyl) 2, so 3h, so 2-nh 2, so 2nh (c 1-c 6)-alkyl, so 2n[(c 1-c 6)-alkyl] 2, s-(c 1-c 6)-alkyl, s-(ch 2) n-aryl, s-(ch 2) n-heterocyclic radical, so-(c 1-c 6)-alkyl, so-(ch 2) n-aryl, so-(ch 2) n-heterocyclic radical, so 2-(c 1-c 6)-alkyl, so 2-(ch 2) n-aryl, so 2-(ch 2) n-heterocyclic radical, so 2-nh (ch 2) n-aryl, so 2-nh (ch 2) n-heterocyclic radical, so 2-n ((c 1-c 6)-alkyl) (ch 2) n-aryl, so 2-n ((c 1-c 6)-alkyl) (ch 2) n-heterocyclic radical, so 2-n ((ch 2) n-aryl) 2, so 2-n ((ch 2) n-(heterocyclic radical) 2, wherein n can be 0-6, and aryl or heterocyclic radical can be replaced twice at the most by following groups: f, cl, br, oh, cf 3, sf 5, no 2, cn, ocf 3, o-(c 1-c 6)-alkyl, (c 1-c 6)-alkyl, nh 2c (nh) (nh 2), nh 2, nh-(c 1-c 6)-alkyl, n ((c 1-c 6)-alkyl) 2, nh (c 1-c 7)-acyl group, nh-co-(c 1-c 6)-alkyl, nh-coo-(c 1-c 6)-alkyl, nh-co-aryl, nh-co-heterocyclic radical, nh-coo-aryl, nh-coo-heterocyclic radical, nh-co-nh-(c 1-c 6)-alkyl), nh-co...
대사 증후군 치료용 약제를 제조하기 위한 치환된사이클로프로판산 유도체의 용도본 발명은 대사 증후군 치료용 약제를 제조하기 위한 치환된 사이클로프로판산 유도체 및 이의 생리학적으로 허용되는 염에 관한 것이다. 본 발명에 따르면, 화학식 I의 화합물 및 이의 생리학적으로 허용되는 염은 대사 증후군 치료용 약제의 제조에 사용된다. 화학식 I  상기 식에서, 치환체의 정의는 명세서에 정의된 바와 같다. 대사 증후군 치료용 약제의 제조를 위한 화학식 I의 화합물 및 이의 생리학적으로 허용되는 염의 용도. [이미지] 상기 화학식 I에서, R1은 알킬, 알케닐, 알키닐, 아릴 및 헤테로사이클릴 라디칼이 F, Cl, Br, I, CF3, NO2, N3, CN, COOH, COO(C1-C6)-알킬, CONH2, CONH(C1-C6)-알킬, CON[(C1-C6)-알킬]2, 사이클로알킬, (C1-C10)-알킬, (C2-C6)-알케닐, (C2-C6)-알키닐, O-(C1-C6)-알킬 O-CO-(C1-C6)-알킬, O-CO-(C1-C6)-아릴, O-CO-(C1-C6)-헤테로사이클릴에 의해 1회 이상 치환될 수 있는, H, (C1-C20)-알킬, (C2-C20)-알케닐, (C2-C20)-알키닐, 아릴, 헤테로사이클릴; n은 0 내지 6일 수 있고, 아릴 라디칼 또는 헤테로사이클릭 라디칼이 F, Cl, Br, OH, CF3, SF5, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2에 의해 2회까지 치환될 수 있는, PO3H2, P(O)(O알킬)2, (C1-C6)-알킬렌-P(O)(O알킬)2, O-P(O)(OH)2, O-P(O)(O알킬)2, SO3H, SO2-NH2, SO2NH(C1-C6)-알킬, SO2N[(C1-C6)-알킬]2, S-(C1-C6)-알킬, S-(CH2)n-아릴, S-(CH2)n-헤테로사이클릴, SO-(C1-C6)-알킬, SO-(CH2)n-아릴, SO-(CH2)n-헤테로사이클릴, SO2-(C1-C6)-알킬, SO2-(CH2)n-아릴, SO2-(CH2)n-헤테로사이클릴, SO2-NH(CH2)n-아릴, SO2-NH(CH2)n-헤테로사이클릴, SO2-N((C1-C6)-알킬)(CH2)n-아릴, SO2-N((C1-C6)-알킬)(CH2)n-헤테로사이클릴, SO2-N((CH2)n-아릴)2, SO2-N((CH2)n-(헤테로사이클릴)2 ; n이 0 내지 6일 수 있고, 아릴 및 헤테로사이클릴 라디칼이 F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-CH3, COOH, COO-(C1-C6)-알킬, CONH2에 의해 1회 내지 3회 치환될 수 있는, C(NH)(NH2), NH2, NH-(C1-C6)-알킬, N((C1-C6)-알킬)2, NH(C1-C7)-아실, NH-CO-(C1-C6)-알킬, NH-COO-(C1-C6)-알킬, NH-CO-아릴, NH-CO-헤테로사이클릴, NH-COO-아릴, NH-COO-헤테로사이클릴, NH-CO-NH-(C1-C6)-알킬, NH-CO-NH-아릴, NH-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-(C1-C6)-알킬, N[(C1-C6)-알킬]-COO-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-아릴, N[(C1-C6)-알킬]-CO-헤테로사이클릴, N[(C1-C6)-알킬]-COO-아릴, N[(C1-C6)-알킬]-COO-헤테로사이클릴, N[(C1-C6)-알킬]-CO-NH-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-NH-아릴, N[(C1-C6)-알킬]-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)2, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-아릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N(아릴)2, N[(C1-C6)-알킬]-CO-N(헤테로사이클릴)2, N(아릴)-CO-(C1-C6)-알킬, N(헤테로사이클릴)-CO-(C1-C6)-알킬, N(아릴)-COO-(C1-C6)-알킬, N(헤테로사이클릴)-COO-(C1-C6)-알킬, N(아릴)-CO-아릴, N(헤테로사이클릴)-CO-아릴, N(아릴)-COO-아릴, N(헤테로사이클릴)-COO-아릴, N(아릴)-CO-NH-(C1-C6)-알킬, N(헤테로사이클릴)-CO-NH-(C1-C6)-알킬, N(아릴)-CO-NH-아릴, N(헤테로사이클릴)-CO-NH-아릴, N(아릴)-CO-N((C1-C6)-알킬)2, N(헤테로사이클릴)-CO-N((C1-C6)-알킬)2, N(아릴)-CO-N[(C1-C6)-알킬]-아릴, N(헤테로사이클릴)-CO-N[(C1-C6)-알킬]-아릴, N(아릴)-CO-N(아릴)2, N(헤테로사이클릴)-CO-N(아릴)2, 아릴, O-(CH2)n-아릴, O-(CH2)n-헤테로사이클릴이고, R2는 알킬, 알케닐, 알키닐, 아릴, 사이클로알킬 및 헤테로사이클릴 라디칼이 F, Cl, Br, I, CF3, NO2, N3, CN, COOH, COO(C1-C6)알킬, CONH2, CONH(C1-C6)알킬, CON[(C1-C6)알킬]2, 사이클로알킬, (C1-C10)-알킬, (C2-C6)-알케닐, (C2-C6)-알키닐, O-(C1-C6)-알킬 O-CO-(C1-C6)-알킬, O-CO-(C1-C6)-아릴, O-CO-(C1-C6)-헤테로사이클릴에 의해 1회 이상 치환될 수 있는, (C1-C20)-알킬, (C2-C20)-알케닐, (C2-C20)-알키닐 아릴, (C3-C7)-사이클로알킬, 헤테로사이클, n이 0 내지 6일 수 있고, 아릴 라디칼 또는 헤테로사이클릴 라디칼이 F, Cl, Br, OH, CF3, SF5, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2에 의해 2회까지 치환될 수 있는, PO3H2, P(O)(O알킬)2, (C1-C6)-알킬렌-P(O)(O알킬)2, O-P(O)(OH)2, O-P(O)(O알킬)2, SO3H, SO2-NH2, SO2NH(C1-C6)-알킬, SO2N[(C1-C6)-알킬]2, S-(C1-C6)-알킬, S-(CH2)n-아릴, S-(CH2)n-헤테로사이클릴, SO-(C1-C6)-알킬, SO-(CH2)n-아릴, SO-(CH2)n-헤테로사이클릴, SO2-(C1-C6)-알킬, SO2-(CH2)n-아릴, SO2-(CH2)n-헤테로사이클릴, SO2-NH(CH2)n-아릴, SO2-NH(CH2)n-헤테로사이클릴, SO2-N((C1-C6)-알킬)(CH2)n-아릴, SO2-N((C1-C6)-알킬)(CH2)n-헤테로사이클릴, SO2-N((CH2)n-아릴)2, SO2-N((CH2)n-(헤테로사이클릴)2 ; n이 0 내지 6일 수 있고, 아릴 또는 헤테로사이클릴 라디칼이 F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-알킬, (C1-C6)-알킬, NH2, NH(C1-C6)-알킬, N((C1-C6)-알킬)2, SF5, SO2-CH3, COOH, COO-(C1-C6)-알킬, CONH2에 의해 1회 내지 3회 치환될 수 있는, C(NH)(NH2), NH2, NH-(C1-C6)-알킬, N((C1-C6)-알킬)2, NH(C1-C7)-아실, NH-CO-(C1-C6)-알킬, NH-COO-(C1-C6)-알킬, NH-CO-아릴, NH-CO-헤테로사이클릴, NH-COO-아릴, NH-COO-헤테로사이클릴, NH-CO-NH-(C1-C6)-알킬, NH-CO-NH-아릴, NH-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-(C1-C6)-알킬, N[(C1-C6)-알킬]-COO-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-아릴, N[(C1-C6)-알킬]-CO-헤테로사이클릴, N[(C1-C6)-알킬]-COO-아릴, N[(C1-C6)-알킬]-COO-헤테로사이클릴, N[(C1-C6)-알킬]-CO-NH-(C1-C6)-알킬, N[(C1-C6)-알킬]-CO-NH-아릴, N[(C1-C6)-알킬]-CO-NH-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)2, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-아릴, N[(C1-C6)-알킬]-CO-N((C1-C6)-알킬)-헤테로사이클릴, N[(C1-C6)-알킬]-CO-N(아릴)2, N[(C1-C6)-알킬]-CO-N(헤테로사이클릴)2, N(아릴)-CO-(C1-C6)-알킬, N(헤테로사이클릴)-CO-(C1-C6)-알킬, N(아릴)-COO-(C1-C6)-알킬, N(헤테로사이클릴)-COO-(C1-C6)-알킬, N(아릴)-CO-아릴, N(헤테로사이클릴)-CO-아릴, N(아릴)-COO-아릴, N(헤테로사이클릴)-COO-아릴, N(아릴)-CO-NH-(C1-C6)-알킬, N(헤테로사이클릴)-CO-NH-(C1-C6)-알킬, N(아릴)-CO-NH-아릴, N(헤테로사이클릴)-CO-NH-아릴, N(아릴)-CO-N((C1-C6)-알킬)2, N(헤테로사이클릴)-CO-N((C1-C6)-알킬)2, N(아릴)-CO-N[(C1-C6)-알킬]-아릴, N(헤테로사이클릴)-CO-N[(C1-C6)-알킬]-아릴, N(아릴)-CO-N(아릴)2, N(헤테로사이클릴)-CO-N(아릴)2, 아릴, O-(CH2)n-아릴, O-(CH2)n-헤테로사이클릴이고, R3, R4, R5, R6 는 서로 독립적으로 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, (C1-C6)-알킬, O-(C1-C6)-알킬이다.